hello, putadon de AMRN....
empiezan las revisiones de PO, Cannacord lo baja de 26 a 19$
http://www.streetinsider.com/Analyst+Comments/Canaccord+Trims+PT+on+Amarin+%28AMRN%29%3B+Sees+Increased+Commercial+Risk%2C+Still+Positive+on+NCE/7931925.html?si_client=st
Un artículo de opoinion que me ha gustado de seeking
http://seekingalpha.com/article/1003301-the-latest-on-amarin-how-will-the-investment-pay-off
me gusta esta conclusión final, despues de un artículo explicado muy bien a mi parecer
"AMRN investors should get excited, but do need to manage expectations. While $30-40 is quite reasonable for a buyout, $50+ would only occur should they partner up or go-it alone, and that would require more time, money and risk"
NPSP comprita de Insiders el pasado 19/11/12,
11,000shares Purchase at $9.09 $99,990
http://www.sec.gov/Archives/edgar/data/890465/000147406412000066/xslF345X03/edgar.xml
esos paquetes pueden ser reestructuración de fondos?o algo asi, Ya me llamó la atención en su día, y lo puse por aqui, la que mires lo tiene
x ejemplo en AMRN salen tb los gemelos
13:00:00 $ 11.21 28,342
13:00:00 $ 11.21 28,342
Read more: http://www.nasdaq.com/symbol/amrn/time-sales#ixzz2D4lZiLOj
X ejemplo APPL tb
13:00:00 $ 571.75 295,528
13:00:00 $ 571.75 295,528
Read more: http://www.nasdaq.com/symbol/aapl/time-sales#ixzz2D4llMufE
PSTI
http://finance.yahoo.com/news/pluristem-reports-status-orphan-drug-110000193.html
"We look forward to providing the additional information that the FDA needs in connection with our orphan drug status application for Aplastic Anemia. We appreciate the very productive working relationship we have with the FDA, as we present PLX cells as candidates for the treatment of a range of therapeutic indications," stated Zami Aberman, Chairman and CEO of Pluristem.
"Orphan drug designation qualifies a company for several benefits under the Orphan Drug Act of 1983 (ODA), as amended. These benefits include a 7-year period of orphan drug exclusivity upon product approval..."
una que no teniamos en el radar http://finance.yahoo.com/q?s=MAPP&ql=1 un +20% hoy
MAPP, hoy aprobación de LEVADEX por FDA y velón verde, en 6 meses revisión
http://finance.yahoo.com/news/map-pharmaceuticals-trade-higher-fda-133703208.html
AMRN Leerink Swann Reiterates its Outperform Rating and Price Target of $27 on Amarin Corporation Shares
http://boardvote.com/symbol/AMRN/communique/129245
como curiosidad, x lo menos, aunque sea alguna vez, pero pillan a alguien los de la SEC...
http://www.streetinsider.com/Hedge+Funds/Hedge+Fund+Heavy+Steve+Cohen+Implicated+in+Massive+Insider+Trading+Scheme/7895029.html